Last reviewed · How we verify

NCT02477579

A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions

Completed NA Last updated 17 August 2017
What this trial tests

NA trial testing NovaCross in Chronic Total Occlusion of Coronary Artery in 145 participants. Completed in 10 August 2017.

Timeline
17 May 2015
Primary endpoint
10 August 2017
10 August 2017

Quick facts

Lead sponsorNitiloop Ltd.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment145
Start date17 May 2015
Primary completion10 August 2017
Estimated completion10 August 2017
Sites5 locations across United States, Poland

Drugs / interventions tested

Conditions studied

Sponsor

Nitiloop Ltd.

Who can join

Adults 18 to 80, any sex, with Chronic Total Occlusion of Coronary Artery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the safety and effectiveness of the a novel device called NovaCross to help cross Chronic Total Occlusion (CTO) lesions in coronary arteries.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of NovaCross

Trials testing the same drug.

Other recruiting trials for Chronic Total Occlusion of Coronary Artery

Currently open trials in the same condition.

Other Nitiloop Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02477579.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing